This year, the Albert Lasker Basic Medical Research Award will be shared by Peter Walter and Kazutoshi Mori for discoveries revealing the molecular mechanism of the unfolded protein response, an intracellular quality control system that detects harmful misfolded proteins in the endoplasmic reticulum and then signals the nucleus to carry out corrective measures.
Our cells communicate with their environment using secreted proteins and proteins displayed on the cell surface. In order to reach their destinations, these proteins must enter the secretory pathway via insertion into the endoplasmic reticulum (ER), where they are folded and matured. Initially, the UPR was all about stress and how our cells handle assaults that result in the incapacity of the ER to fold proteins. Today, it is recognized that the UPR works normally as a homeostat that keeps the cell's protein folding capacity balanced with its needs and is especially important in cells that professionally secrete proteins such as immunoglobulin-secreting plasma cells.
The prologue to the discovery of the UPR begins with the scientific enquiry into what happens to cells when they are stressed with heat. The answer is that nearly all cell types from yeast to mammals transcriptionally upregulate a set of genes encoding heat-shock proteins (HSP). When cells are stressed under conditions such as increased temperature, many proteins are unstable and become misfolded. HSPs bind to denatured proteins that have a tendency to form insoluble aggregates and help solubilize them. The first indication that this process also occurs in the secretory pathway appeared in the late 1980s, with an observation from Hugh Pelham's laboratory. During the course of isolating cDNA clones for HSPs, they discovered that one HSP homolog contained a signal peptide targeting it to be localized within the ER. This protein had previously been identified as both a glucose-regulated protein (GRP) and an immunoglobulin heavy-chain binding protein (BiP). Putting two and two together, HSPs were subsequently shown to bind to misfolded proteins in the cytoplasm/nucleus. In an analogous way, BiP (GRP78) was shown to bind to incompletely folded proteins in the secretory pathway. In addition, BiP was released from its binding partners by the addition of ATP, similar to the way HSPs are released from their substrates. Therefore, BiP seemed to function in the ER in the same manner as heat-shock proteins in the cytoplasm/nucleus. Thus, the conceptual framework was established for differentiating between the heat-shock effect in the cytoplasm mediated by the heat-shock proteins and the unfolded protein response in the ER mediated by the GRPs. This body of work collectively birthed the UPR and set the stage for Peter Walter at the University of California, San Francisco (USA) and Kazutoshi Mori at Kyoto University (Japan) to pursue the molecular mechanisms responsible for these phenomena.
The First Steps
Walter and Mori independently took advantage of the yeast, Saccharomyces cerevisiae, as a model system to begin studying the UPR. Although their approaches were different, they consistently arrived at the same conclusions. Instances in which key findings are independently discovered and confirmed by separate groups are rare and result in an accelerated pace of discovery. This was the case with Walter and Mori.
The story begins in the early 1990s, when Kazutoshi Mori, a postdoctoral fellow in the laboratories of Mary-Jane Gething and Joseph Sambrook, initiated studies on the S. cerevisiae KAR2 (BiP) gene and defined a 22 bp UPR promoter element (UPRE) that stimulates the activity of a heterologous promoter in response to the presence of unfolded proteins in the ER (Mori et al., 1992) . Using this information as the basis for a genetic screen, they identified a class of mutants unable to respond to the presence of unfolded proteins in the ER. In these studies, they describe the ERN1 gene, which encodes a 1115 amino acid transmembrane protein belonging to the CDC28/cdc2+ family of serine threonine kinases (Mori et al., 1993) . Concomitantly, Peter Walter's laboratory used the UPRE defined by Mori in a genetic screen of their own design with a different readout and isolated mutants that fail to induce KAR2 mRNA in response to unfolded proteins in the ER. Surprisingly, they had identified the same gene as Mori but retained the previously reported name, IRE1 (Cox et al., 1993) . This work represented an important clue because IRE1 was initially cloned by complementation of a yeast mutant auxotrophic for inositol, which was known to be essential for ER expansion. Thus, this observation highlighted the connection between the UPR and the expansion of the ER that was a postulated prerequisite for its upregulation.
Both groups speculated that Ire1p would function in the ER similarly to how other transmembrane kinases function in the plasma membrane, specifically that its N-terminal domain would be localized in the lumen of the ER. There, it could sense unfolded proteins, perhaps via interactions with BiP, and would transmit that signal to the cytoplasmic kinase domain. The kinase domain would then phosphorylate downstream protein(s), thereby transmitting the signal to the nucleus, where the transcription of various genes encoding proteins important for the UPR could be activated. Due to the contiguous nature of the nuclear membrane and the ER, it was also postulated that Ire1p is positioned with its kinase domain in the nucleus. Although the general ideas put forth in Walter's and Mori's initial reports would prove to be true, the molecular mechanism used by Ire1p to transmit the signal to the nucleus is decidedly unconventional. In fact, this mechanism would prove to be so unexpected that unraveling it required returning to the early stages of their work in order to characterize and understand the transcription factor that binds to the UPRE.
Still in step, Walter and Mori (now at the HSP Research Institute in Kyoto, Japan) independently identified Ern4p/Hac1p as the transcription factor that controlled the UPR. Both groups recognized that Hac1p binds to the UPRE and activates the transcription of genes involved in ER stress. Walter's group also reported that the cellular level of Hac1p is regulated by splicing of its mRNA in an Ire1p-dependent fashion (Cox and Walter, 1996; Mori et al., 1996) . They went on to show that Hac1p translated from spliced mRNA (encoding Hac1p i ) differs from the protein encoded by unspliced mRNA (encoding Hac1p u ) in that Hac1p i accumulates in cells to attain a concentration sufficient to activate transcription of its target genes. They also noted that the splice junctions of HAC1 mRNA do not conform to the consensus of spliceosomemediated splicing and that splicing is not blocked in spliceosome-defective mutants. This unique nonconventional splicing is the first example of splicing as an obligatory regulatory step in a signal transduction pathway and resulted in a paradigm shift in our thinking about RNA splicing. Mori's group confirmed these results and made a critical discovery that the absence of Hac1p in unstressed cells is not due to differences in protein or mRNA stability but, rather, is due to a lack of translation (Kawahara et al., 1997) . Collectively, these observations launched the next round of investigations focused on this unusual regulatory mRNA splicing.
Ire1's Surprising Mechanism
Walter and colleagues took a closer look at bioinformatic information, which suggested that Ire1p's C terminus closely resembles RNase L, as both proteins harbored a kinase domain and a nuclease domain (Sidrauski and Walter, 1997 mRNA was indeed transported from the nucleus into the cytoplasm, where it associated with polyribosomes in an unproductive manner. The presence of the intron attenuated mRNA translation not only in the context of its own RNA, but also when it was spliced to the 3 0 untranslated region of a heterologous RNA. This was the first report of a new mechanism by which RNA translation could be controlled.
Branching Out
Up until the late 1990s, Walter's and Mori's groundbreaking work had been carried out in S. cerevisiae. Whether metazoans would use a conserved system to initiate their UPR remained an open question. Enter Randal Kaufman and David Ron, whose groups independently tackled this problem using classic bioinformatics and molecular biology techniques to clone mammalian Ire1p. They concluded that human Ire1p is an essential proximal sensor of the UPR in mammalian cells and functions much like yeast Ire1p. Ron's laboratory also showed that human Ire1p upregulates the expression of the CHOP/GADD153 (CCAAT/enhancer binding protein homologous protein/growth arrest DNA damage 153) gene. This was in agreement with prior data demonstrating not only that ER stress upregulates ER resident proteins and chaperones, but also that chronic ER stress is linked to programmed cell death, a situation in which CHOP played a predominant role. By the end of the 20th century, Ire1 and the molecular mechanism by which it functioned in UPR were known to be highly First, the UPR in metazoans was to become more complicated. Ire1p is solely responsible for the UPR in yeast, but higher organisms have multiple mechanisms in place to fine-tune this important cell biology problem. It had long been known that protein synthesis and correct folding of ER resident and secreted proteins is modulated under stress conditions by phosphorylation of eIF-2a. Phosphorylated eIF-2a attenuates protein translation, presumably lessening the ER burden. In keeping with the coincident publication standard set by Walter and Mori, Ronald Wek and David Ron discovered a new kinase involved in ER stress that phosphorylates eIF-2a on Ser-51 (Harding et al., 1999; Shi et al., 1998) . Their publications appeared a month apart, with their chosen names for the kinase differing by only one letter, PEK versus PERK, respectively. The PERK catalytic domain is related to eIF-2a kinases, and PERK kinase activity similarly results in downregulation of protein translation. Unlike other eIF-2a kinases, PERK contains a signal peptide destining it for integration into the ER membrane. PERK's domain architecture is similar to Ire1 without the nuclease domain. This arrangement placed the kinase domain in the cytoplasm, where it phosphorylates its target, eIF-2a. Cellular conditions that result in the phosphorylation of eIF-2a include but are not limited to starvation of amino acids, glucose, or serum, as well as growth factor deprivation, heat shock, and unfolded proteins. Presumably, the N-terminal domain of PERK senses one or more of these conditions in the ER and increases its kinase activity, resulting in preferentially reduced translation of proteins destined for the secretory pathway.
Concordantly, Mori's laboratory discovered a third member of the UPR triad, ATF6 (activating transcription factor 6) (Yoshida et al., 1998) . In yeast, the UPRE was originally defined as a cis-acting DNA element specified by the partially palindromic sequence CAGCGTG that is necessary and sufficient for induction of the KAR2 gene encoding yeast GRP78/ BiP. Similarly, the mammalian UPR can be largely specified by the unique sequence CCAAT-N9-CCACG. This cisacting element is designated the ER stress response element (ERSE), and it is necessary and sufficient for the induction of at least three ER chaperones. Mori's group used this sequence in a yeast one-hybrid screen for DNA-binding proteins and obtained the bZIP (basic leucine zipper domain) protein ATF6. ATF6 is a constitutively expressed 90 kDa protein that is embedded in the ER but is converted to a 50 kDa nuclearlocalized protein upon ER stress. ATF6 is a type II transmembrane glycoprotein with the hydrophobic membrane spanning amino acids located in the middle of the molecule. The N-terminal half contains a basic leucine zipper motif that resides in the cytoplasm, whereas the C-terminal domain is localized within the lumen and presumably senses ER stress. ER stress induces transport to the Golgi apparatus, and proteolysis releases the cytoplasmic domain, which translocates into the nucleus and, in cooperation with the general transcription factor NF-Y, activates transcription of the endogenous BiP gene among other targets. This mechanism of action is eerily similar to that reported for cholesterol homeostasis, wherein depletion of sterols results in the cleavage of SREBPs, thus permitting the transfer of the N-terminal transcription factor to the nucleus, where it enhances transcription of target genes involved in cholesterol homeostasis.
The work described above defined the major triad of the UPR and began to define the molecular machines it employs. Yet, there were still many questions to be answered, in particular, what was the mammalian equivalent of HAC1?
and Beyond
As was mentioned previously, mammalian Ire1 had been characterized and was shown to be similar to yeast Ire1p in its domain architecture and enzymatic properties. However, no mammalian HAC1 counterpart had been identified. While looking into ATF6 targets, Mori's group identified the long-sought transcription factor XBP1 . Like HAC1, XBP1 mRNA is spliced by IRE1, and only the protein translated from the spliced mRNA form could activate the UPR effectively. XBP1 had been difficult to find because it shares essentially no sequence identity at the nucleotide or amino acid level with Hac1. However, it is a bZIP protein like ATF6 though it binds DNA markedly differently, thereby inducing a different set of target genes. Working with Mori's group, Kaufman and his colleagues characterized the UPR response in C. elegans and demonstrated that it consists of both the ire-1 and pek-1 branches. Using the XBP1 amino acid sequence reported by Mori's group, they found the C. elegans XBP1 ortholog, which is a bZIP protein that surprisingly shares no amino acid homology with human XBP1 or yeast Hac1p except within the bZIP region (Shen et al., 2001) . However, its mRNA is spliced by IRE1, thus preserving the general regulatory mechanism defined by HAC1 mRNA splicing in yeast. Working independently, Ron's laboratory also characterized the UPR in C. elegans. Using an elegant genetic screen, they identified XBP1 and confirmed that IRE1-mediated processing of XBP1 mRNA is conserved (Calfon et al., 2002) .
Although we have a good mechanistic understanding of how the UPR functions, there were still perplexing questions that await resolution. For example, does IRE1 phosphorylate a protein target other than itself, and is autophosphorylation necessary for the UPR? In collaboration with Kevan Shokat, Walter's group (Papa et al., 2003) mutated the Ire1 kinase domain such that it becomes an ATP competitive inhibitor. Unexpectedly, the drug-sensitized Ire1p still induces a full UPR, indicating that conformational changes within the kinase domain are induced by occupancy of the active site with ligand and not that phosphorylation per se activates downstream functions. Indeed, structural studies by Robert Stroud and Walter on a drug-activated Ire1p have shown that it oligomerizes into a rod-shaped assembly heretofore unseen among kinases. Structural studies on the N-terminal domain demonstrated that it also oligomerizes, forming a deep groove architecturally similar to the binding pockets that occur in the peptide-binding domain of the major histocompatibility complex (MHC). Because these domains in the MHC bind directly to unstructured peptides, it has been proposed by analogy that the groove in Ire1 also binds unfolded proteins in the ER (Gardner and Walter, 2011) . These structural studies are critical to the design of drugs to combat UPR-associated diseases.
Concluding Remarks
The unfolding of this story eloquently exposes the molecular mechanisms responsible for the complex cell biology problem known as the UPR. The inability of cells to deal with misfolded proteins is now recognized as the underpinning for many human diseases. Examples of diseases that can be defined by protein misfolding or ER overload include retinitis pigmentosa and type II diabetes. Even some types of cancer subvert the cytoprotective role of the UPR to maintain rapid growth. One hope is that future efforts to treat these diseases will be facilitated by a better mechanistic and structural understanding of the UPR. We congratulate this year's Lasker Basic Medical Research Award recipients on their remarkable discoveries and astounding progress. Undoubtedly, the future harbors many interesting and unforeseen plots yet to unfold.
